The prevention effect in renal disease patients taking a oral steroid with the rebamipide or the rabeprazole- a randomized control study-

The prevention effect in renal disease patients taking a oral steroid with the rebamipide or the rabeprazole- a randomized control study- - The prevention effect in renal disease patients taking a oral steroid with the rebamipide or the rabeprazole- a randomized control study-

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001611

Enrollment

Registered

2009-01-05

Start date

2008-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal disease

Interventions

This randomized, single-center study was conducted according to the Declaration of Helsinki. We asked the patients about the following 6 symptoms: early satiety

belching

daytime heartburn

nocturnal heartburn

epigastric pain

or discomfort. All of dyspepsia symptoms were rated by patients on a seven-point categorical scale (0

none, 1: slight, 2: mild, 3: moderate, 4: severe, 5: very severe, 6: worst possible. When patients have a score less than 3 points for 6 symptoms and patients do not have peptic ulcer by endoscopic f

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: renal disease patients with taking a oral steroid at the graduate School of Medicine Science, Kumamoto University.

Exclusion criteria

Exclusion criteria: Patients were excluded if patients had been malignant disease, previous upper abdominal surgery, neuropsychiatric disorder, organic brain damage, hepato-renal disorder, cardiopulmonary disorder, symptoms suggesting or were pregnant.

Design outcomes

Primary

Measure	Time frame
The current study attempted to compare the efficacy of rabeprazole with rebamipide after 12-week treatment in renal disease patients taking a oral steroid with or without H. pylori infections.	—

Secondary

Measure	Time frame
Gastrointestinal symptom.(Gastrointesitinal Symptom Rating Scale) upper gastrointestinal endoscopy.	—

Countries

Japan

Contacts

Public ContactKouichi Sakurai

Graduate School of Medicine Science, Kumamoto University Department of Gastroenterology and Hepatology

sakurai@s3.kcn-tv.ne.jp096-373-5150(+81-96-373-5150)

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026